These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 36211665

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H, Kearns I, Young M, Humphries MJ, Trueman D.
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [Abstract] [Full Text] [Related]

  • 8. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L, Sheng Z, Zhang J, Song J, Teng L, Liu L, Li Q, Wang B, Li B.
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [Abstract] [Full Text] [Related]

  • 9. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [Abstract] [Full Text] [Related]

  • 10. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y, Zhao Q, Liao Z, Ma Y, Ma D.
    Cancer; 2023 Apr 15; 129(8):1261-1275. PubMed ID: 36748799
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ, Canestaro W, Ravelo A, Wong W.
    J Med Econ; 2017 Jul 15; 20(7):671-677. PubMed ID: 28332433
    [Abstract] [Full Text] [Related]

  • 14. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct 15; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
    Guan H, Sheng Y, Guo W, Han S, Shi L.
    Adv Ther; 2019 May 15; 36(5):1114-1125. PubMed ID: 30900201
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.